{"filing":{"accession_number":"0001193125-26-342388","cik":"0001785279","ticker":"MGX","company_name":"Metagenomi Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"mgx-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm"},"events":[{"id":26575,"run_id":24157,"accession_number":"0001193125-26-342388","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes condensed financial statements (balance sheet and statements of operations), cash position ($120.7 million), R\u0026D and G\u0026A expenses, net loss per share ($0.73), and business updates regarding the MGX-001 hemophilia A program. The press release is furnished as Exhibit 99.1 and contains both financial results and operational milestones typical of an earnings announcement.","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27745,"accession_number":"0001193125-26-342388","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes condensed financial statements (balance sheet and statements of operations), cash position ($120.7 million), R\u0026D and G\u0026A expenses, net loss per share ($0.73), and business updates regarding the MGX-001 hemophilia A program. The press release is furnished as Exhibit 99.1 and contains both financial results and operational milestones typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:18:33.009974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27745,"accession_number":"0001193125-26-342388","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes condensed financial statements (balance sheet and statements of operations), cash position ($120.7 million), R\u0026D and G\u0026A expenses, net loss per share ($0.73), and business updates regarding the MGX-001 hemophilia A program. The press release is furnished as Exhibit 99.1 and contains both financial results and operational milestones typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:18:33.009974+00:00","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-08-10"}]}